167 related articles for article (PubMed ID: 25800647)
1. Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Li P; Basnet SK; Kumarasiri M; Diab S; Teo T; Albrecht H; Wang S
Eur J Med Chem; 2015 May; 95():116-26. PubMed ID: 25800647
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.
Teo T; Lam F; Yu M; Yang Y; Basnet SK; Albrecht H; Sykes MJ; Wang S
Mol Pharmacol; 2015 Aug; 88(2):380-9. PubMed ID: 26044548
[TBL] [Abstract][Full Text] [Related]
4. An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
Teo T; Yang Y; Yu M; Basnet SK; Gillam T; Hou J; Schmid RM; Kumarasiri M; Diab S; Albrecht H; Sykes MJ; Wang S
Eur J Med Chem; 2015 Oct; 103():539-50. PubMed ID: 26408454
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
Zhang M; Jiang L; Tao J; Pan Z; He M; Su D; He G; Jiang Q
Bioorg Med Chem; 2019 Jun; 27(11):2268-2279. PubMed ID: 31014565
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.
Diab S; Abdelaziz AM; Li P; Teo T; Basnet SKC; Noll B; Rahaman MH; Lu J; Hou J; Yu M; Le BT; Albrecht H; Milne RW; Wang S
Eur J Med Chem; 2017 Oct; 139():762-772. PubMed ID: 28863357
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.
Basnet SK; Diab S; Schmid R; Yu M; Yang Y; Gillam TA; Teo T; Li P; Peat T; Albrecht H; Wang S
Mol Pharmacol; 2015 Nov; 88(5):935-48. PubMed ID: 26268528
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
13. Dynamical insights of Mnk2 kinase activation by phosphorylation to facilitate inhibitor discovery.
Kumarasiri M; Teo T; Wang S
Future Med Chem; 2015; 7(2):91-102. PubMed ID: 25685999
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis and Bioactivity Evaluation of 4,6-Disubstituted Pyrido[3,2-
Xing K; Zhang J; Han Y; Tong T; Liu D; Zhao L
Molecules; 2020 Sep; 25(18):. PubMed ID: 32967084
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening.
Mishra RK; Clutter MR; Blyth GT; Kosciuczuk EM; Blackburn AZ; Beauchamp EM; Schiltz GE; Platanias LC
Chem Biol Drug Des; 2019 Oct; 94(4):1813-1823. PubMed ID: 31260185
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2-d]pyrimidine derivatives as Mnk1/2 inhibitors.
Xing K; Zhang H; Wang S; Li J; Mu Z; Zhang L; Zuo S; Wang Y; Li S; Wu B; Jing Y; Wen J; Liu D; Huang M; Zhao L
Eur J Med Chem; 2024 Jun; 272():116499. PubMed ID: 38759457
[TBL] [Abstract][Full Text] [Related]
17. Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.
Kwiatkowski J; Liu B; Pang S; Ahmad NHB; Wang G; Poulsen A; Yang H; Poh YR; Tee DHY; Ong E; Retna P; Dinie N; Kwek P; Wee JLK; Manoharan V; Low CB; Seah PG; Pendharkar V; Sangthongpitag K; Joy J; Baburajendran N; Jansson AE; Nacro K; Hill J; Keller TH; Hung AW
J Med Chem; 2020 Jan; 63(2):621-637. PubMed ID: 31910010
[TBL] [Abstract][Full Text] [Related]
18. Progress in developing MNK inhibitors.
Jin X; Yu R; Wang X; Proud CG; Jiang T
Eur J Med Chem; 2021 Jul; 219():113420. PubMed ID: 33892273
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
20. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
